Sagimet Biosciences Inc
For the period ended Dec 31, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended December 31, | ||||||
| · · 2024 · · 2023 | ||||||
| Cash flows from operating activities · · | ||||||
| Net loss | | $(45,567) | | $(27,876) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Accretion of discount on marketable securities | | (1,253) | | (37) | ||
| Non-cash operating lease expense | | 145 | | 139 | ||
| Stock-based compensation expense | | 5,288 | | 4,990 | ||
| Change in fair value of Series A common stock warrant liability | | | — | | | (4) |
| Changes in operating assets and liabilities: | | | | |||
| Prepaid expenses and other current assets | | (5) | | (952) | ||
| Accounts payable, accrued expenses and other current liabilities | | (907) | | 120 | ||
| Operating lease liabilities | | (136) | | (146) | ||
| Net cash used in operating activities | | (42,435) | | (23,766) | ||
| Cash flows from investing activities | | | ||||
| Purchases of marketable securities | | | (108,087) | | | (19,620) |
| Sales and maturities of marketable securities | | 46,404 | | 32,200 | ||
| Net cash (used in) provided by investing activities | | (61,683) | | 12,580 | ||
| Cash flows from financing activities | | | ||||
| Proceeds from sale of Series A common stock, net of issuance costs | | | 105,750 | | | — |
| Proceeds from initial public offering, net of underwriters' commissions and discounts | | | — | | | 89,679 |
| Payment of financing costs | | (1,045) | | (3,518) | ||
| Proceeds from exercise of stock options | | | 114 | | | 6 |
| Net cash provided by financing activities | | 104,819 | | 86,167 | ||
| Net increase in cash and cash equivalents | | 701 | | 74,981 | ||
| Cash and cash equivalents at beginning of period | | 75,139 | | 158 | ||
| Cash and cash equivalents at end of period | | $75,840 | | $75,139 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Deferred financing costs included in accrued expenses | | $— | | $323 | ||
| Conversion of redeemable convertible preferred stock to Series A and Series B common stock | | $— | | $214,620 | ||
| Reclassification of common stock to Series A common stock | | $— | | $1 | ||
| Right-of-use assets obtained in exchange for operating lease obligations | | $149 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.